Table 5. Comparison of treatment response to sorafenib and lenvatinib in the 40 patients with HCC.
| Response to lenvatinib | CR and PR | SD | PD | P value |
|---|---|---|---|---|
| Response to previous sorafenib | ||||
| PR (N = 6) | 6 (100%) | 0 (0%) | 0 (0%) | P < 0.001* |
| SD (N = 20) | 4 (20%) | 16 (80%) | 0 (0%) | |
| PD (N = 14) | 1 (7.1%) | 0 (0%) | 13 (92.9%) |
Notes.
- HCC
- hepatocellular carcinoma
- CR
- complete response
- PR
- partial response
- SD
- stable disease
- PD
- progressive disease
*
Statistically significant.